Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARADIGM: TPF Induction vs Chemoradiotherapy in Head and Neck Cancer
NCT00095875Phase 3Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2004
- Primary completion
- Apr 2012
- Modality
- Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of docetaxel, Cisplatin micelle injection (HA132) and fluorouracil in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Overall Survival at 3 years. Started Aug 2004; status: completed.
02
Drugs
docetaxelCisplatin micelle injection (HA132)fluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00095875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095875.